Incobotulinumtoxin A

Phase 2Small molecule

UUniversity of Utah

Incobotulinumtoxin A is one of 9 small molecule programs targeting Alopecia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AlopeciaActive, not recruiting

AlopeciaPhase 2

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Alopecia

#DrugCompanyPhaseTrials

Otezla

Amgen

Approved

1 2

Trexall

Jazz Pharmaceuticals

Approved

1 3

Opzelura

Zolymbus

Olumiant

Rogaine

1 7

Plaquenil

Jazz Pharmaceuticals

Preclinical

1 8

Xeljanz

PPrism Pharmaceuticals

Preclinical

1 9

Incobotulinumtoxin A

UUniversity of Utah

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alopecia1 trial

Use of Botulinum Toxin in the Treatment of Androgenic Alopecia

Active, not recruiting·ZZel Skin and Laser Specialists·Phase 2·NCT05456087·20 enrolled

Synkinesis1 trial

Comparison of Three Botulinum Neuromodulators for Management of Facial Synkinesis

Completed·UUniversity of Utah·Phase 4·NCT03048383·71 enrolled

Borderline personality disorder1 trial

Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD)

Completed·HHannover Medical School·Phase 2·NCT02728778·54 enrolled

Dystonia1 trial

Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand

Completed·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT02107261·21 enrolled

Treatment1 trial

Retrospective Evaluation of Combination Treatment With the Ulthera System

Completed·UUlthera, Inc··NCT02444169·101 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Incobotulinumtoxin A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Incobotulinumtoxin A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Incobotulinumtoxin A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Utah company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Utah

Incobotulinumtoxin A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alopecia1 trial

Synkinesis1 trial

Borderline personality disorder1 trial

Dystonia1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News